Cargando…
Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
With the rapid development of targeted therapies for the treatment of cancer, methods for predicting response and outcome are in high demand. Non-small cell lung cancer driven by genomic rearrangements of the anaplastic lymphoma kinase (ALK) gene can be successfully treated with ALK-targeted therapy...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226192/ https://www.ncbi.nlm.nih.gov/pubmed/32290439 http://dx.doi.org/10.3390/cancers12040947 |
_version_ | 1783534232830738432 |
---|---|
author | Madsen, Anne Tranberg Winther-Larsen, Anne McCulloch, Tine Meldgaard, Peter Sorensen, Boe Sandahl |
author_facet | Madsen, Anne Tranberg Winther-Larsen, Anne McCulloch, Tine Meldgaard, Peter Sorensen, Boe Sandahl |
author_sort | Madsen, Anne Tranberg |
collection | PubMed |
description | With the rapid development of targeted therapies for the treatment of cancer, methods for predicting response and outcome are in high demand. Non-small cell lung cancer driven by genomic rearrangements of the anaplastic lymphoma kinase (ALK) gene can be successfully treated with ALK-targeted therapy. Unfortunately, a subset of patients does not respond, and all patients ultimately acquire resistance, highlighting the need for better clinical tools to manage these patients. Here, we performed targeted next-generation sequencing on plasma circulating tumor DNA (ctDNA) from 24 patients to assess the clinical utility of ctDNA genomic profiling. Patients with detectable ctDNA prior to treatment had worse progression-free survival (PFS) than those without (median 8.7 vs. 15.2 months, p = 0.028). In addition, the presence of ctDNA within two months after treatment initiation predicted inferior PFS (median 4.6 vs. 14.5 months, p = 0.028). Longitudinal monitoring of ctDNA with droplet digital PCR during treatment reflected the radiological response and revealed potential acquired resistance mutations. Interestingly, an increase in the ctDNA concentration was evident prior to the determination of progressive disease by conventional radiological imaging, with a median lead time of 69 days (range 30–113). Genomic profiling of ctDNA is a promising tool for predicting outcome and monitoring response to targeted therapy. |
format | Online Article Text |
id | pubmed-7226192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72261922020-05-18 Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients Madsen, Anne Tranberg Winther-Larsen, Anne McCulloch, Tine Meldgaard, Peter Sorensen, Boe Sandahl Cancers (Basel) Article With the rapid development of targeted therapies for the treatment of cancer, methods for predicting response and outcome are in high demand. Non-small cell lung cancer driven by genomic rearrangements of the anaplastic lymphoma kinase (ALK) gene can be successfully treated with ALK-targeted therapy. Unfortunately, a subset of patients does not respond, and all patients ultimately acquire resistance, highlighting the need for better clinical tools to manage these patients. Here, we performed targeted next-generation sequencing on plasma circulating tumor DNA (ctDNA) from 24 patients to assess the clinical utility of ctDNA genomic profiling. Patients with detectable ctDNA prior to treatment had worse progression-free survival (PFS) than those without (median 8.7 vs. 15.2 months, p = 0.028). In addition, the presence of ctDNA within two months after treatment initiation predicted inferior PFS (median 4.6 vs. 14.5 months, p = 0.028). Longitudinal monitoring of ctDNA with droplet digital PCR during treatment reflected the radiological response and revealed potential acquired resistance mutations. Interestingly, an increase in the ctDNA concentration was evident prior to the determination of progressive disease by conventional radiological imaging, with a median lead time of 69 days (range 30–113). Genomic profiling of ctDNA is a promising tool for predicting outcome and monitoring response to targeted therapy. MDPI 2020-04-11 /pmc/articles/PMC7226192/ /pubmed/32290439 http://dx.doi.org/10.3390/cancers12040947 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Madsen, Anne Tranberg Winther-Larsen, Anne McCulloch, Tine Meldgaard, Peter Sorensen, Boe Sandahl Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients |
title | Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients |
title_full | Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients |
title_fullStr | Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients |
title_full_unstemmed | Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients |
title_short | Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients |
title_sort | genomic profiling of circulating tumor dna predicts outcome and demonstrates tumor evolution in alk-positive non-small cell lung cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226192/ https://www.ncbi.nlm.nih.gov/pubmed/32290439 http://dx.doi.org/10.3390/cancers12040947 |
work_keys_str_mv | AT madsenannetranberg genomicprofilingofcirculatingtumordnapredictsoutcomeanddemonstratestumorevolutioninalkpositivenonsmallcelllungcancerpatients AT wintherlarsenanne genomicprofilingofcirculatingtumordnapredictsoutcomeanddemonstratestumorevolutioninalkpositivenonsmallcelllungcancerpatients AT mccullochtine genomicprofilingofcirculatingtumordnapredictsoutcomeanddemonstratestumorevolutioninalkpositivenonsmallcelllungcancerpatients AT meldgaardpeter genomicprofilingofcirculatingtumordnapredictsoutcomeanddemonstratestumorevolutioninalkpositivenonsmallcelllungcancerpatients AT sorensenboesandahl genomicprofilingofcirculatingtumordnapredictsoutcomeanddemonstratestumorevolutioninalkpositivenonsmallcelllungcancerpatients |